North America Medical Isotope Production Market Size, Share & Trends Analysis Report By Isotope Type (Diagnostic Isotopes, Therapeutic Isotopes), By Production Technology (Nuclear Reactor-Based Production, Fission-based, Neutron activation, Cyclotron-Based Production), By Country (U.S., Canada) and Forecast, 2026-2034

North America Medical Isotope Production Market Trends

Transition Toward Domestic, Non-HEU and Accelerator-Enabled Production

Supply-chain localization is accelerating as the United States seeks alternatives to imported Mo-99. More than 40,000 U.S. medical procedures per day use Tc-99m, while Tc-99m accounts for roughly 80–85% of nuclear-medicine procedures globally and is used in more than 30 million procedures annually. U.S. policy has simultaneously moved production away from proliferation-sensitive materials; DOE reports that all major global Mo-99 production facilities had converted to non-HEU processes by 2023.

Technology diversification is increasingly visible across fission, neutron activation, proton acceleration and deuteron-driven systems. DOE has supported 8 companies developing 14 technologies for domestic Mo-99 production, while an electrically powered D-D neutron system described by DOE produces more than 10^9 neutrons per second. Emerging fusion research also indicates that few-megawatt neutron sources could potentially manufacture substantial quantities of several therapeutic and diagnostic radionuclides, broadening the technology base beyond conventional research reactors.

North America Medical Isotope Production Market Drivers

Expanding Nuclear Medicine Utilization and Domestic Supply Requirements

More than 40,000 Tc-99m procedures occur daily in the United States, equivalent to roughly 14.6 million procedures annually at a constant daily rate, creating persistent requirements for dependable Mo-99 availability. The United States represents nearly 50% of global Mo-99 demand, yet continues to depend heavily on overseas supply, creating strong incentives for localization. Federal intervention has included 8 industry partners, 14 production technologies, and a planned Medicare add-on payment of USD 10 for qualifying domestically sourced Mo-99 radiopharmaceuticals beginning in 2026.

North America Medical Isotope Production Market Restraints

Short Half-Lives, Capital Intensity and Concentrated Production Infrastructure

Radioisotope logistics remain unusually restrictive: Tc-99m has a half-life of approximately 6 hours, while its Mo-99 parent has a half-life near 66 hours, limiting inventory buffers and increasing sensitivity to reactor, processing and transportation interruptions. Historically, bulk Mo-99 supply depended on only about 5 industrial producers and 8 irradiation reactors, while fission production yields approximately 6.1% Mo-99, demonstrating the technical concentration behind supply vulnerability.

North America Medical Isotope Production Market Opportunities

Expansion of Therapeutic Isotope Capacity and Advanced Domestic Manufacturing

Targeted radionuclide therapy is opening opportunities beyond the established diagnostic isotope supply chain. In 2026, DOE announced a conditional commitment of up to USD 263 million toward SHINE's Wisconsin facility, following federal support that included USD 32 million identified in 2025 when construction was approximately 75% complete. Parallel research indicates that D-T fusion platforms operating at only a few megawatts could potentially manufacture isotopes including Lu-177, Cu-67 and Sc-47, creating additional routes for high-specific-activity therapeutic materials.

Challenges in North America Medical Isotope Production Market

Maintaining Reliable Supply During Infrastructure and Technology Transition

The central challenge is simultaneously maintaining established isotope availability and commercializing new production routes. Global Tc-99m utilization exceeds 30 million procedures annually, while U.S. utilization exceeds 40,000 procedures daily. Meanwhile, emerging facilities require substantial financing, licensing and commissioning: SHINE's project received a conditional federal loan commitment of up to USD 263 million in 2026, illustrating the capital scale required before new domestic capacity can materially diversify supply.

North America Medical Isotope Production Market Segmentation

The industry is segmented by isotope type, production technology, application and end-user. Among categories for which mandatory numerical tables were supplied, diagnostic isotopes dominate with approximately 56.5% of 2026 isotope-type revenue, compared with about 43.5% for therapeutic isotopes. Diagnostic isotopes also record the higher supplied CAGR at 8.53%.

By Isotope Type

Diagnostic isotopes are the largest category, increasing from USD 941.80 million in 2025 to USD 1,022.14 million in 2026 and USD 1,967.46 million by 2034, with an 8.53% CAGR. Their approximately 56.5% 2026 contribution reflects extensive use of radionuclides in nuclear diagnostic imaging.

Therapeutic isotopes increase from USD 727.46 million in 2025 to USD 787.40 million in 2026 and USD 1,483.54 million by 2034, recording an 8.24% CAGR. Diagnostic isotopes remain the faster-growing supplied category at 8.53% CAGR.

By Production Technology

Production technology includes nuclear reactor-based production through fission and neutron activation, alongside cyclotron-based proton acceleration and deuteron reactions. No segment-level monetary values were supplied for this classification; accordingly, no unsupported revenue or CAGR is assigned. Reactor systems remain important for high-volume radionuclides, while accelerator platforms enable decentralized production and alternative reaction pathways.

The fastest-growing technology cannot be numerically ranked from the mandatory dataset because no technology-specific CAGR was provided. Commercial decisions increasingly consider beam energy, target recovery, isotope yield and processing time, with facilities frequently requiring 24/7 operational coordination where products have half-lives measured in hours rather than years.

By Application

Applications comprise diagnostic, therapeutic and research uses. The supplied isotope data indicate diagnostic isotope revenue of USD 1,022.14 million in 2026 and USD 1,967.46 million by 2034, at an 8.53% CAGR, supporting diagnostics as the principal monetized use environment represented by the dataset.

Therapeutic isotope revenue reaches USD 787.40 million in 2026 and carries an 8.24% CAGR, while no separate research-application CAGR was supplied. Consequently, a numerically defensible fastest-growing application cannot be established independently from isotope-type classifications.

By End-User

Hospitals and clinics, diagnostic imaging centers, academic and research institutes, pharmaceutical and biotechnology companies, and contract research organizations form the principal customer base. The supplied tables provide 2 isotope categories and 2 country markets, but no end-user revenue allocation or CAGR; therefore, fabricated end-user values are excluded.

Hospitals and imaging facilities are structurally important because U.S. Tc-99m utilization exceeds 40,000 procedures per day, while pharmaceutical and biotechnology demand is expanding alongside targeted radiopharmaceutical development. No supplied end-user CAGR permits identification of a statistically supported fastest-growing end-user category.

North America Medical Isotope Production Market Counties Outlook

U.S.

The United States contributes approximately 79.6% of the supplied North American 2026 country total. Revenue rises from USD 1,329.40 million in 2025 to USD 1,439.47 million in 2026 and is forecast to reach USD 2,720.13 million by 2034, representing an 8.28% CAGR. Its contribution remains near four-fifths of regional revenue, supported by hospitals, imaging centers, radiopharmaceutical companies and domestic isotope-production initiatives.

Canada

Canada represents approximately 20.4% of the supplied 2026 regional total, increasing from USD 339.86 million in 2025 to USD 368.68 million in 2026 and USD 707.05 million by 2034 at an 8.48% CAGR. Its CAGR exceeds the U.S. rate by 0.20 percentage points, supported by established nuclear infrastructure and isotope-processing expertise.

Top players in the North American Medical Isotope Production Market

1. BWX Technologies, Inc.
2. Curium Pharma
3. NorthStar Medical Radioisotopes
4. SHINE Technologies
5. Nordion
6. Cardinal Health
7. Lantheus Holdings
8. Jubilant Radiopharma
9. Eckert & Ziegler
10. GE HealthCare
11. Novartis
12. Telix Pharmaceuticals
13. Ionetix
14. Niowave
15. Kinectrics

Industry participant lists include BWXT Medical, Curium, NorthStar, Nordion, Lantheus, Cardinal Health, Jubilant, and other radiopharmaceutical suppliers.

Top Two Companies

• BWX Technologies, Inc.

A verified company-level percentage share is not publicly disclosed in the sources reviewed, so no unsupported percentage is assigned. BWXT participates in medical-isotope manufacturing and processing, while its Kinectrics operation announced expanded isotope-separation capacity in 2025, including what it described as the only North American Yb-176 source. This positioning connects BWXT with Lu-177 supply chains as therapeutic radiopharmaceutical programs expand. The company operates within a North American environment where diagnostic Tc-99m alone supports more than 40,000 U.S. procedures daily, while new therapeutic isotopes are broadening addressable production requirements.

• SHINE Technologies

A verified percentage revenue share is likewise not publicly disclosed; therefore, an invented market-share percentage is excluded. SHINE has strategic positioning in planned U.S. Mo-99 localization. In 2026, DOE announced a conditional loan commitment of up to USD 263 million for its Chrysalis facility. In 2025, the facility was reported to be approximately 75% complete, with SHINE selected for USD 32 million in additional federal support. The project targets domestic commercial Mo-99 supply through fusion- and fission-linked technology, addressing a U.S. requirement exceeding 40,000 Tc-99m procedures every day.

Recent Developments in the North American Medical Isotope Production Market

• 2026: The U.S. DOE announced a conditional commitment of up to USD 263 million for SHINE Chrysalis to support completion of its Wisconsin medical-isotope manufacturing facility.
• 2026: The NRC approved direct and indirect transfer of the SHINE Medical Isotope Production Facility construction permit to SHINE Chrysalis, LLC, with the order dated April 28, 2026.
• 2025: Kinectrics completed a major isotope-production expansion in Toronto, establishing a North American source for enriched Yb-176, a precursor relevant to Lu-177 production.
• 2025: NNSA selected SHINE for USD 32 million in support when its Mo-99 facility was approximately 75% complete, while CMS proposed a USD 10 domestic Mo-99 radiopharmaceutical add-on payment for 2026.
• 2025: An updated OECD-NEA analysis reported Tc-99m use in more than 30 million procedures annually and approximately 80–85% of nuclear medicine procedures, underscoring continued dependence on secure isotope production infrastructure.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, with 2022–2024 forming the historical framework. Mandatory user-supplied numerical tables are treated as the primary source for revenue, country contribution, isotope contribution and CAGR; calculated percentages use only those supplied values. External evidence is limited to contextual production, utilization, technology and company developments. Where the supplied country and isotope tables report different totals—USD 1,808.15 million versus USD 1,809.54 million in 2026, and USD 3,427.18 million versus USD 3,451.00 million in 2034—each dataset is preserved without reconciliation or alteration.